{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mutation+analysis&page=3", "query": { "intervention": "mutation analysis", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 276, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mutation+analysis&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mutation+analysis&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T09:14:28.870Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02728258", "title": "Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Metastatic Endometrioid Adenocarcinoma", "Recurrent Uterine Corpus Cancer" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2016-09-16", "completion_date": "2020-02-14", "has_results": true, "last_update_posted_date": "2022-02-15", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 43, "location_summary": "New Haven, Connecticut • Deerfield Beach, Florida • Miami, Florida + 35 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02728258" }, { "nct_id": "NCT01857271", "title": "Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2013-11", "completion_date": "2017-08-31", "has_results": true, "last_update_posted_date": "2020-07-08", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 3, "location_summary": "New York, New York • The Bronx, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01857271" }, { "nct_id": "NCT01630447", "title": "Genetic and Functional Analysis of Cherubism", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cherubism" ], "interventions": [], "intervention_types": [], "sponsor": "UConn Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 600, "start_date": "2009-04", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 1, "location_summary": "Farmington, Connecticut", "locations": [ { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01630447" }, { "nct_id": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Gilteritinib Fumarate", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 1400, "start_date": "2020-07-21", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 186, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04293562" }, { "nct_id": "NCT01503619", "title": "Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2012-01", "completion_date": "2019-02-27", "has_results": false, "last_update_posted_date": "2021-08-17", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01503619" }, { "nct_id": "NCT03317119", "title": "Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Carcinoma", "RAS Family Gene Mutation", "Stage III Colon Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Rectal Cancer AJCC v7", "Stage IIIA Colon Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIA Rectal Cancer AJCC v7", "Stage IIIB Colon Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIB Rectal Cancer AJCC v7", "Stage IIIC Colon Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IIIC Rectal Cancer AJCC v7", "Stage IV Colon Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Rectal Cancer AJCC v7", "Stage IVA Colon Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVA Rectal Cancer AJCC v7", "Stage IVB Colon Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Stage IVB Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-04-11", "completion_date": "2023-07-14", "has_results": false, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 8, "location_summary": "Corona, California • Duarte, California • Lancaster, California + 5 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03317119" }, { "nct_id": "NCT01783795", "title": "Dent Disease Mutation Genotyping", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dent Disease" ], "interventions": [ { "name": "Genetic Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 180, "start_date": "2012-08", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2020-04-06", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01783795" }, { "nct_id": "NCT03091257", "title": "A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-06-21", "completion_date": "2026-09-15", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Detroit, Michigan", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03091257" }, { "nct_id": "NCT00717587", "title": "Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "motexafin gadolinium", "type": "DRUG" }, { "name": "sunitinib malate", "type": "DRUG" }, { "name": "comparative genomic hybridization", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "iodine I-124 girentuximab", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2008-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00717587" }, { "nct_id": "NCT00551421", "title": "Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "pertuzumab", "type": "BIOLOGICAL" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "fluorescence in situ hybridization", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" }, { "name": "mutation analysis", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2007-10", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2015-03-31", "last_synced_at": "2026-10-17T09:14:28.870Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551421" } ] }